Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài:"Tuberculosis chemotherapy: current drug delivery approaches. | Respiratory Research BioMed Central Review Open Access Tuberculosis chemotherapy current drug delivery approaches Lisa Claire du Toit Viness Pillay and Michael Paul Danckwerts Address University of the Witwatersrand Faculty of Health Sciences Department of Pharmacy and Pharmacology 7 York Road Parktown 2193 South Africa Email Lisa Claire du Toit - lisad@ Viness Pillay - Michael Paul Danckwerts - Corresponding author Published 19 September 2006 Respiratory Research 2006 7 118 doi 1465-9921-7-1 18 Received 02 July 2006 Accepted 19 September 2006 This article is available from http content 7 1 1 18 2006 du Toit et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Tuberculosis is a leading killer of young adults worldwide and the global scourge of multi-drug resistant tuberculosis is reaching epidemic proportions. It is endemic in most developing countries and resurgent in developed and developing countries with high rates of human immunodeficiency virus infection. This article reviews the current situation in terms of drug delivery approaches for tuberculosis chemotherapy. A number of novel implant- microparticulate- and various other carrier-based drug delivery systems incorporating the principal anti-tuberculosis agents have been fabricated that either target the site of tuberculosis infection or reduce the dosing frequency with the aim of improving patient outcomes. These developments in drug delivery represent attractive options with significant merit however there is a requisite to manufacture an oral system which directly addresses issues of unacceptable rifampicin bioavailability in fixed-dose combinations.
